When a cancer cell doesn't respond to traditional therapies, doctors may turn to a sort of viral biological warfare, by deploying 'troops' in the form of viral agents that are specifically engineered to target and eliminate cancer cells. The mode of attack is to transform the tumor...
“The cancer immunity cycle, as we understand it today, is actually incomplete—we’re missing the crucial step of T cell reactivation within the tumor microenvironment,” says Anais Elewaut, co-first author of the study and a student in the Vienna BioCenter PhD Program. “We discovere...
New hopes for bowel cancer sufferers ; Stem cell research breakthroughKELLY MACNAMARA
Asbiotechhas gone from strength to strength over the past four decades, China has been a backwater for the industry, tending to follow the west rather than pursuing its own innovations. But it is now rapidly emerging as a world leader in cell therapies like Car-T, which try to treat and...
Microenvironment Center at UPMC Hillman Cancer Center. “We make millions of T cells and we infuse them back into a patient, but most of the cells die. Our research is uncovering new ways to manufacture T cells that live for a long time with the goal of making cell therapies more ...
Myeloid cells are a type of white blood cell that patrols the body looking for pathogens, but there are actually two sub-types of them. The M1 macrophage has been found to suppress tumor growth, while M2s do the opposite – they fight off helpful T cells (the foot soldiers of the immune...
Dr. Christopher E. Rudd, a researcher at the Centre de recherche de l'Hôpital Maisonneuve-Rosemont (CR-HMR) and Université de Montréal, has discovered a new cell therapy approach that boosts the immune response of T lymphocytes to malignant tumours.
52]. It can be detected in memory and activated T cells, regulatory T cells, NK and NKT cells, follicular helper T cells, and cytokine-induced killer cells [45]. Studies have shown that TIGIT can dampen the response of the T cell in an extracellular and cell-intrinsic manner through the...
The development of CAR T cell-based cancer immunotherapy marked a breakthrough in the treatment of leukemia, but the approach has not yet made significant strides against solid tumors due, at least in part, to a lack of tumor-specific targets. In these cancers, most of the proteins responsibl...
The history of CSCs ability to drive tumorigenesis is long, but the real breakthrough came in the 1990s and 2000s [2,3,4,5,6]. The low number of CSCs, occurring at a frequency of 1–100 in 10−6 [2] is a serious obstacle for cell isolation and similarly, and non-specific marke...